Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thallion Pharmaceuticals Inc.

Latest From Thallion Pharmaceuticals Inc.

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

India Pushing Ahead With Rare Disease Policy Plan

India appears to be on course to developing a national rare disease policy, with the adoption of a specific definition for rare diseases and the initiation of a rare disease registry in the country.

Policy Rare Diseases

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Commercial Deals

Thallion attempts to tame Jaguar ahead of Bellus acquisition vote

Canadian firm Thallion Pharmaceuticals will hold a shareholder meeting on 6 August to vote on the proposed acquisition of Thallion by Bellus Health. Thallion's board is keen for the deal to proceed, but its largest single shareholder, Jaguar Financial which holds 10.1%, has indicated it will vote against the deal unless terms are increased.

Metabolic Disorders Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ecopia BioSciences
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Thallion Pharmaceuticals Inc.
  • Senior Management
  • Alan Mandelzys, PhD, CEO
    Michael Singer, CFO
    Didier Reymond, MD, EVP, Clinical Dev.
  • Contact Info
  • Thallion Pharmaceuticals Inc.
    Phone: (514) 940-3600
    1375 TransCanada Hwy., Ste. 200
    Dorval, H9P 2W8